Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance

Boston Scientific CorporationTrade
Charles Schwab Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs Charles Schwab Corporation Common Stock — how do they compare? Boston Scientific Corporation trades at $51.55 (market cap $74.19B), while Charles Schwab Corporation Common Stock trades at $109.34 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 2.5× Boston Scientific Corporation's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

BSXSCHW
Market Cap
$74.19B$186.25B
Sector
HealthFinancials
52-Week High
$108.14$108.02
52-Week Low
$42.63$85.35
Enterprise Value
$86.27B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Charles Schwab Corporation Common Stock

Charles Schwab (SCHW) trades at $109.28, up 1.19% today, near its all-time high of $109.05 (Zacks Investment Research, 2026-08-07). The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue grew to $23.92 billion in 2025, with net income margin expanding to 37%, while analyst consensus is bullish with a $122.33 price target. Recent news highlights insider selling and ongoing litigation, but institutional acquisitions signal confidence.

Outlook remains positive driven by earnings growth and market share gains, but risks include regulatory scrutiny from lawsuits (Business Wire, 2026-08-10) and interest rate sensitivity. The stock offers upside to consensus targets, though overbought conditions suggest potential near-term volatility. Investors should weigh robust fundamentals against macroeconomic and legal headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About Charles Schwab Corporation Common Stock

Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.

Read more on SCHW